title: Modulation of paclitaxel resistance by annexin IV in human cancer cell lines.
abstract: A recurring problem with cancer therapies is the development of drug resistance. While investigating the protein profile of cells resistant to a novel antimitotic compound (A204197), we discovered an increase in annexin IV expression. When we examined the annexin IV protein expression level in a paclitaxel-resistant cell line (H460/T800), we found that annexin IV was also overexpressed. Interestingly a closely related protein, annexin II, was not overexpressed in H460/T800 cells. Immunostaining with either annexin II or IV antibody revealed that annexin IV was primarily located in the nucleus of paclitaxel-resistant H460/T800 cells. Short-term treatment of H460 cells with 10 nM paclitaxel for up to 4 days resulted in induction of annexin IV, but not annexin II expression. In addition, there was an increase in annexin IV staining in the nucleus starting at day 1. Furthermore, cells pretreated with 10 nM paclitaxel for 4 days resulted in cells becoming approximately fivefold more resistant to paclitaxel. Transfection of annexin IV cDNA into 293T cells revealed that there was a threefold increase in paclitaxel resistance. Thus our results indicate that annexin IV plays a role in paclitaxel resistance in this cell line and it is among one of the earliest proteins that is induced in cells in response to cytotoxic stress such as antimitotic drug treatment.
authors.affiliation: Cancer Research, Department 4N6, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
authors.forename: E K
authors.initials: EK
authors.lastname: Han
authors.forename: S K
authors.initials: SK
authors.lastname: Tahir
authors.forename: S P
authors.initials: SP
authors.lastname: Cherian
authors.forename: N
authors.initials: N
authors.lastname: Collins
authors.forename: S C
authors.initials: SC
authors.lastname: Ng
mesh_terms: D017314:Annexin A4 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015153:Blotting, Western; D003078:Colchicine / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology*; D018076:DNA, Complementary / Q000235:genetics; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D015972:Gene Expression Regulation, Neoplastic; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015739:Nocodazole / Q000494:pharmacology; D017239:Paclitaxel / Q000494:pharmacology*; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D014162:Transfection; D050257:Tubulin Modulators; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
chemical_list: D017314:Annexin A4; D018076:DNA, Complementary; D006131:Growth Inhibitors; D009363:Neoplasm Proteins; D011993:Recombinant Fusion Proteins; D050257:Tubulin Modulators; D017239:Paclitaxel; D015739:Nocodazole; D003078:Colchicine